drugset / Trial / NCT06281964
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2028-06-30
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | PLB1004 | Small molecule | 240 mg | Oral |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Comparator | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |